Overall Survival Improved with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with ...
1. 18-month recurrence-free survival was significantly greater in the combination therapy group compared to pembrolizumab alone. 2. There were no ...
1. Adding chemotherapy to immunotherapy did not prolong OS or PFS, with non-significant differences in HR. 2. Grade 3 or ...
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy ...
1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy ...
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
1. Progression-free survival was significantly greater among patients in the pembrolizumab group compared to placebo (10.0 vs. 8.1 months). 2. ...
1. The median overall survival and event-free survival were not statistically different in the pembrolizumab group as compared to the ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.